The 8th Joint ACTRIMS-ECTRIMS Meeting 2020 (Videos) | Medical Video Courses.

The 8th Joint ACTRIMS-ECTRIMS Meeting 2020 (Videos)

Regular price
$50.00
Sale price
$50.00
Regular price
Sold out
Unit price
per 

The 8th Joint ACTRIMS-ECTRIMS Meeting 2020 (Videos)

44 MP4 Video files

YOU WILL GET THE COURSE VIA LIFETIME DOWNLOAD LINK (FAST SPEED) AFTER PAYMENT

The 8th Joint ACTRIMS-ECTRIMS Meeting

The 8th Joint ACTRIMS-ECTRIMS Meeting, the largest international conference focused on Multiple Sclerosis (MS) research, was held in a virtual format from September 11-13, 2020, with a special encore session featuring Late-Breaking News and a COVID-19 Session on September 26.

Every three years, ACTRIMS and ECTRIMS organize a joint meeting to encourage knowledge exchange and bring together professionals from around the world.

Given the worldwide impact of COVID-19, the 8th Joint ACTRIMS-ECTRIMS Meeting took place virtually. View all scientific sessions, e-posters and teaching courses from MSVirtual2020. 

At this virtual conference – MSVirtual2020 – world class scientists, neurologists, clinicians and researchers from around the world presented the latest research, clinical trial outcomes and technology and diagnostic advances in multiple sclerosis (MS).

Key topics included:

  • Cutting-edge research into the cause of MS, ranging from epigenetics and genetic factors, to defining the intricate immunological and pathological pathways that inform drug discovery and therapeutic interventions.
  • Radiological advances and machine learning approaches and how these techniques can help us better understand MS.
  • Biomarkers of disease activity and response to therapy, which is critical for the future of personalized medicine in MS.
  • The outcomes of recent clinical trials of new agents and interventions, innovations in symptomatic and rehabilitative therapy, and current research on MS and COVID-19.

 

Learning & Program Objectives

The themes for this conference, designed by the MSVirtual2020 Scientific Program Committee are clinical, pathogenesis, translational, and environmental/genetic factors and were derived from past attendee input and emerging studies and literature.
MSVirtual2020 key areas for education:

  • Therapeutic strategies for suppressing disease activity and disability accumulation in individuals with radiologically isolated syndrome, relapsing-remitting MS and progressive MS
  • Efficacy of current disease-modifying therapies across clinical subsets of individuals with MS
  • Role of innate immune cells in pathogenic and reparative pathways in MS
  • Relationship between the gut, microbiome, and disease activity in individuals with MS
  • Advances in imaging and visual system parameters in the diagnosis, prognosis and monitoring of individuals with MS
  • Integration of information on environmental, lifestyle, age-related, and genetic/ epigenetic factors in MS risk and clinical course
  • Use of machine learning approaches in predicting MS risk and clinical course

Sessions included:

  1. BD01 – DMTs prevent-slow down cognitive impairment in MS
  2. BD02 – DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity
  3. BD03 – Microglia are protective in MS
  4. CS01 – European Charcot Foundation Symposium; How to enhance remyelination in MS
  5. FC01 – Free Communication 1
  6. FC02 – Free Communication 2
  7. FC03 – Free Communication 3
  8. FC04 – Free Communication 4
  9. HT01 – Hot Topic 1- Strategies to promote remyelination
  10. HT02 – Hot Topic 2- Aging and MS
  11. HT03 – Hot Topic 3- Developments in pediatric MS
  12. HT04 – Hot Topic 4- Grey matter pathology
  13. HT05 – Hot Topic 5- Lymphoid follicles and meningeal involvement in MS
  14. HT06 – Hot Topic 6- Global perspectives on NMOSD
  15. HT07 – Hot Topic 7- MOG mediated disease
  16. LB01 – Late Breaking News
  17. MTE01 – CNS in disorders in children
  18. MTE02 – Neuro-ophthalmology of MS
  19. MTE03 – B-cell-directed therapy in MS
  20. MTE04 – Choosing the right MS disease therapy for individual patients
  21. MTE05 – Immune disorders of the CNS other than MS
  22. NS01 – Nurses’ Session 1- Advanced nursing activities
  23. NS02 – Nurses’ Session 2- Unique contributions of MS nursing
  24. PL01 – Plenary Session 1- Welcome and Paty Lecture
  25. PL02 – Plenary Session 2- ACTRIMS-ECTRIMS Lecture and Closing
  26. PS01 – Strategies for disease modification
  27. PS02 – Innate immunity in MS pathology and repair
  28. PS03 – Biomarkers
  29. PS04 – Impact of the environment and lifestyle and MS risk and clinical course
  30. PS05 – Pharmacological management of progressive MS
  31. PS06 – Lymphocyte subsets in MS
  32. PS07 – Radiological advances I (NAIMS-MAGNIMS)
  33. PS08 – Epigenetics and genetic factors
  34. PS09 – Personalized approaches to MS
  35. PS10 – Gut-CNS axis and the microbiome in MS
  36. PS11 – Radiological advances II
  37. PS12 – Sex-related factors in pathogenesis and management
  38. PS13 – Innovations in symptomatic and rehabilitative therapy
  39. PS14 – The impact of MS on neurons and glia
  40. PS15 – Visual outcome measures in MS (IMSVISUAL)
  41. PS16 – Machine learning approaches
  42. SS02 – Special Session- COVID-19
  43. YI01 – Young Investigators 1
  44. YI02 – Young Investigators 2
Sale

Unavailable

Sold Out